529
256193226014562122182
Ces8507936014570127174
Urol10497936014578115180208
2018;12827936014562121176230253
22(4):15617936014561121152208239261
251–25618477936014562122177231286346406
PŘEHLEDOVÝ852207016974156235334409485586692777867
ČLÁNEK1757207016989163260360438521
resection85089801313284124177227263285343401
with1283898013179102135193
transurethral150089801314274123181221277308360393451482532554
resection207889801314092132185235271293351409
alone251189801315880138196249
in278489801313189
patients2897898013168118150172225282314356
with3284898013180102136194
stage350289801314883133192245
pTa‑pT13771898013168112153187248292342
urothelial413789801316698154186244298320342390412
carcinoma4573898013157106138184206264322412461
of505889801316694
the5176898013142100153
bladder:850104801316184132192251304336355
which12301048013179137159207265
patients15191048013161111143165218276307349
benefit18921048013161115173226252278311
from2228104801312861118207
the2460104801313492145
instillation?2629104801312380120154176198220268301323380439475
Eur31281048013152107138
Urol.32901048013169100156180198
2016;35121048013154105153200217
69(2):37531048013154105133185211227
231–244.40041048013154107153203250298354372
4.850119601335679
Järvinen952119601334194129185211271326387
R,1363119601335984
Kaasinen14711196013360113166208233293348409
E,1904119601335477
Sankila20051196013354107168219246271323
A,2352119601336792
et2468119601335592
al.2584119601335378101
Long‑term27091198013150107165225258291342374464
efficacy3197119801315481109137185235284335
of3556119801315987
maintenance36681198013190139161219250301359408466514565
bacillus42581198013161111159181203225282321
Calmette‑Guerin46041198013163112135223276309346397431503561614645668725
versus8501348013150102133174230270
maintenance11501348013190139161219250301359408466514565
mitomycin17461348013190112145201291337385406464
C22411348013162
instillation2327134801313087127161183205227276308330388446
therapy2797134801314199152183233293340
in3161134801313087
frequently3272134801313669120180237290348380402450
recurrent3747134801313990140197228261312370402
TaT14173134801315899142193
tumours4390134801314198187246304335376
without47961348013180102136194252310344
car‑51641348013155105136165
cinoma850149801314971128187276325
in1199149801313188
situ:1311149801314970104162179
a15141498013157
subgroup15961498013148105164225256313370430
analysis20501498013158115164186234275296335
of2409149801316695
the25281498013142100153
prospective,27051498013168100157197256310359396418467519535
randomised3265149801314090147207265354376415468529
FinnBladder3818149801315880137195249272321380440493524
I43661498013131
study4421149801314983141200249
with47011498013180102136194
a49191498013158
20-year50011498013161113148196248296328
follow‑up.850164801312986109131189267300359419436
Eur13111648013151106137
Urol14721648013169100157180
2009;16761648013154105160214232
56:19321648013153105123
260.20791648013154105158176
5.850179601335677
Sylvester9461796013354101127179232274311364399
RJ,13641796013359102123
van15061796013352104164
der16891796013362116151
Meijden18601796013387142167192253308368
AP,22471796013367123133
Witjes23991796013392118153178232275
JA,26931796013340104128
et2840179601335591
al.295017960133537799
Bacillus30691798013155104152174195217273312
calmette‑guerin3400179801314998120208260293329379413474531583614636693
versus41121798013150101132172228267
chemotherapy43991798013148105158246303335393445476525584631
for5053179801312582113
the5190179801313087139
intravesical850194801312381112144194242293334355403453475
treatment1349194801313567118166198288341399431
of1804194801315987
patients19161948013160110143165217275307349
with22891948013180102136194
carcinoma2507194801314999130177199256315404453
in2984194801312481
situ308919480131426397154
of3268194801315887
the3379194801313493146
bladder:3549194801316184133192252305336356
a39291948013150
meta‑analysis40041948013190143176226260308366415437485526547586
of4615194801315887
the4726194801313492145
published48961948013161119178201223262319372433
results850209801313284124181203236278
of1152209801315887
randomized1263209801313282140199257347369413464524
clinical181220980131497192150171220269292
trials.212820980131346588136159197217
J23692098013138
Urol.24312098013169100156179198
2005;26532098013153105160212226
174:2904209801315397142159
86.30872098013154108127
6.850224601335679
Malmström9502246013389142167258300337373432524
PU,14952246013358128147
Sylvester16632246013355103129182235278315369405
RJ,20892246013359102124
Crawford2234224601336498151230266326361423
DE,26782246013373127150
et2849224601335592
al.2962224601335378100
An30852248013164122
individual3231224801312179138160209232291348397419
patient36722248013161111143165218276307
data40012248013160109141191
meta‑analysis42142248013190143176225259308365414436484525546585
of4821224801315887
the4932224801313290143
long‑term5099224801312179138197258228216144170
outcome50722248013157042949672164294967200429496716442949671384294967014
of466522480131584294967268
randomised4604224801314294967285429496727042949672324294967175429496711642949670914294966938429496693542949669084294966862
studies40332248013141429496729042949672824294967227429496713442949671434294967080
comparing37182248013149144294967286429496717442949671074294967046429496700942949670264294966978
intravesical3320224801314294967281842949672534294967244429496726142949672712233578120136
mitomycin34722248013189104136190276318364384440
C39302248013162
versus40102248013150100130170225263
bacillus42922248013160108156177198219275313
Calmette‑Guerin46242248013162111132219271303339389423493550601632654710
for850254801312986118
non‑muscle‑invasive9922548013159117176209300357396445467520554578635682732772793842894
bladder1910254801316184133192252305336
cancer.2270254801314999157205256288302
Eur25962548013151106138
Urol2758254801316899156179
2009;29612548013154105160214232
56:32172548013154106123
247.33642548013154102150157
7.850269601335668
Sylvester9432696013354103129181235278315369404
RJ,13732696013359102123
van15222696013353106166
der17132696013362117153
Meijden18912696013389144169195257312373
AP,22892696013367125134
Lamm24492696013351106197288
DL.27622696013373125150
Intravesical2936269801312583115147197244296336358406456478
bacillus34402698013161111159181203225282321
Calmette‑Guerin37872698013163112135223276310346397431503561614645668725
reduces4536269801313587147204252303344
the4904269801313694147
risk507526980131345796141
of5242269801315987
progression850284801316193149210241292333372394451510
in1384284801312178
patients14842848013161111143165218276307349
with18552848013179102135193
superficial2072284801313996155209241270297345367415438
bladder2531284801316184133192252305336
cancer:2889284801314999157205256287307
a32182848013150
meta‑analysis32902848013190143176226259308366415437485525547586
of3897284801315987
the4008284801313290143
published41732848013161119179202223262320373433
results4630284801313082122179201234276
of4927284801315987
rando‑5038284801313181138198256291
mized8502998013190112156207267
clinical114229980131497192150171220269292
trials.145829980131346588136159197217
J16992998013138
Urol.17612998013169100156179198
200219832998013153105160210
168(5):22172998013153100154182233259276
1964–1970.2517299801315499153208265311356406456474
8.850314601335680
Babjuk9513146013359112174200260311
M,12823146013389113
Burger14163146013359119155216271306
M,17433146013388112
Compérat18763146013364123214276332367420456
E,2352314601335577
et2450314601335592
al.2562314601335379101
EAU26853148013151117181
Guidelines28883148013168126148207260283304362415455
on33643148013159117
Non‑Muscle‑Invasive35033148013170128187220307364404452474527562586644691741780802851903
Urothelial44273148013169100156189247300323344392415
Carcinoma48633148013163112144190212270328418466
of850329801315987
the961329801313492145
Bladder:1130329801315679127187246299330350
Update15043298013169128189237269320
2016.18493298013153105153199218
Eur20913298013151107138
Urol.22533298013169100156179198
2017;24753298013154105153197210
71(3):27093298013153102123174199216
447–461.29493298013154110158207263318363376
9.850344601335675
Colombo9493446013364123149209301363423
R,1396344601336085
Da15053446013373125
Pozzo16543446013359117162212272
LF,19503446013352104116
Lev20903446013352107158
A,2272344601336893
et2389344601335591
al.2504344601335378101
Local26293448013150107156206228
microwave28823448013190112160192248326376424476
hyperthermia33823448013159105166220252289347400431521543591
and39983448013150108167
intravesical4189344801312482113145195243295335356404454476
chemotherapy46893448013150108161250308341399452483533593640
as850359801315090
bladder964359801316992141200260313344
sparing13323598013149109159190213270330
treatment1686359801314274125174206295349407439
for2149359801313794126
select22993598013149102125178227264
multifocal25953598013190147169203225253311360410432
and30513598013158116176
unresectable32513598013166124156207247301350387436496519572
superficial38473598013149106165220251281307356378426448
bladder4320359801316892140200259312344
tumors.46883598013142100189247279320340
J50533598013146
Urol.5131359801316999156179198
1998;850374801315499152205222
159:1097374801315398147165
783–787.12863748013154104156211258309358366
10.8503896013356107129
Curley9983896013364122157183238288
SA,13063896013354120144
Palalon14703896013359110135187213273334
F,1823389601335466
Sanders19093896013354107167229283319363
KE,22923896013359114137
Koshkina24483896013360118161221272299359411
NV.28793896013372133150
The30493898013151111164
effects3233389801315482112164213249291
of3544389801315987
non‑invasive36523898013158117175208231289336386425447496547
radiofrequency4223389801312979138160218246279330390447500558607657
treatment4904389801313162114162194283336394425
and8504048013151110171
hyperthermia10464048013168116178234266304364418451543565615
on16864048013168128
malignant18474048013192142165188248307358417450
and23224048013159118179
nonmalignant25264048013169128188279329352375435495545604637
cells.31884048013158110134156196216
Int3429404801313292124
J35784048013147
Environ36504048013161120168192224282342
Res40174048013165120161
Public42034048013165123184208230280
Health.45164048013171125174198232291311
2014;48524048013163116165213230
11(9):51074048013163105127177204222
9142–9453.8504198013154102148197249302356406455473
11.8504346013356101118
Brisuda988434601336096121164223285337
A,1345434601336892
Babjuk14584346013359112174200260311
M,17894346013388112
Stolz1921434601335489148173220
J.2161434601334162
Intravezikální2248434801312078110141191239291335358403454476533555
chemoterapie28244348013149107160249307339390422472531554606
s34554348013137
využitím35134348013150102160204227260282371
tepelné3908434801313182141195218275328
energie42574348013154112165196254276328
u46064348013158
pacientů46854348013161111160181234292324381
s50904348013138
uro‑5149434801315889146181
teliálním850449801313485107128176198255277365
karcinomemmočového12354498013147971281751962543114014545426527107598158629149721030
měchýře22854498013190142191249295327378
bez26834498013160114158
invaze2865449801312077124173217269
svaloviny3154449801314191140162220268291348394
–35684498013155
zkušenosti3643449801314490148186239297354394428450
jednoho4117449801312072132190248306364
pracoviště.4501449801316192142190246294316355389440456
Ces49774498013163113153
Urol51504498013169100156179
2017;8504648013154105153197210
21(2):10844648013153101122173199216
122–128.1324464801315498151203249293344364
12.8504796013356104127
Colombo10044796013363122148208300362423
R,1453479601335984
Da15634796013374126
Pozzo17154796013359117162212272
LF,20104796013355108120
Salonia21564796013354108133193254279331
A,2514479601336792
et2632479601335592
al.2750479601335378101
Multicentric28784798013186143165198220269320378409441464512
study3414479801314479136196244
comparing36824798013153108198258308339362419478
intravesical4185479801312683115147197244296336358406456478
chemotherapy46874798013152110163252310343401454485535595642
alone850494801315072130189242
and11154948013149107167
with13054948013179101135193
local1522494801312280130179201
microwave17464948013190112160192248327376424476
hyperthermia22454948013158105165219251288346399430520542590
for2859494801312885117
prophylaxis2999494801316193149210268314337386434456495
of3517494801315987
recurrence3628494801313183132190221253305363411462
of4113494801315987
superficial4224494801314096156210241271297346368416438
transitional4686494801313365115172212233266288346405453476
cell5185494801314999122144
carcinoma.850509801314999130177199256314404453472
J13465098013138
Clin1408509801316385106164
Oncol.15965098013174132181237260278
2003;18995098013153105160210226
21(23):21495098013153101122173226251267
4270–4276.24405098013154103153203261317366416463483
13.8505246013356105126
Colombo9985246013364123149209300362423
R,1443524601335984
Salonia15495246013355108133193254279331
A,1902524601336892
Leib20165246013352107132194
Z,2232524601336184
Pavone‑Macaluso23385246013358110160219280335371461514563616642701744804
M,31645246013389113
Engelstein32995246013354114175230256298335389414474
D.3795524601337493
Long‑term39115248013149106165224257290341373463
outcomes43965248013159117150197253342395436
of4854524801315987
a49645248013150
rando‑5038524801313181139198256291
mized8505398013190112156207267
controlled11425398013152108167198230287310332384445
trial161153980131376992140162
comparing17975398013153109199258308339362419479
thermochemotherapy2300539801313896149180270328378436489578636668726780811861920968
with32955398013180102136194
mitomycin‑C35165398013191112146202291337385407464498563
alone4104539801315375133192245
as4373539801315493
adjuvant44905398013154113136192242292349381
treatment4895539801313870121169201291344402434
for850554801312986118
non‑muscle‑invasive9925548013159117176209300357396445467520554578635682732772793842894
bladder1910554801316184133192252305336
cancer2270554801314999157205256288
(NMIBC).2582554801312997182204259321351366
BJU2972554801315692160
Int.3156554801312481113132
2011;33125548013154106153194205
107:35415548013153100150163
912–918.37285548013154102147198251299346365
14.8505696013356106128
Arends9975696013367102157217279321
TJ,1338569601335488109
Nativ14665696013373125160185238
O,1723569601337695
Maffezzini18385696013388141172204259306355381441465
M,23235696013388112
et2455569601335591
al.2565569601335378101
Results26875698013155108148205227260301
of3008569801315987
a31155698013150
randomised3189569801312878136195253342364403455515
controlled37255698013149104163194226282305327379439
trial418856980131306284132155
comparing43635698013149104194253303334356414473
intravesical4860569801311976108139189237288328349397447469
chemohyperthermia8505848013149106159247305363409469523554590648701732821843890
with17605848013179102135192
mitomycin19725848013190111144200289335382403460
C24525848013162
versus25345848013150101132173229268
bacillus28225848013160110158179201222279318
Calmette‑Guérin31605848013162111133221274307343393428499557609640662719
for3903584801312582113
adjuvant40365848013150109131187236286343374
treatment4434584801313062113160192281334391422
of4876584801315987
patients49835848013160109141163215273304345
with8505998013179102135193
Intermediate-1067599801312481113164196286339399421469501552587
and16785998013150108167
High‑risk1869599801316991150208241274297336381
Non‑Muscle‑invasive22745998013170128187220307364403452474527562585643690740779801850902
Bladder3200599801315578127186246299330
Cancer.35545998013163113170219270301315
Eur38935998013152107138
Urol.40555998013169100156180198
2016;42775998013154105153200217
69(6):45185998013154105133183210226
1046–1052.47695998013153100156211268315362413463481
15.8506146013356105126
Lammers9956146013352106197288343379423
RJ,14376146013359103124
Witjes15816146013393119155180235277
JA,18786146013341105130
Inman2031614601332383174226286
BA,23376146013360125150
et2506614601335592
al.2617614601335379101
The27386148013151111164
role2926614801312985108161
of3107614801315987
a32146148013150
combined32856148013149104194253276333386446
regimen3755614801312980141162251304362
with41376148013179102135193
intravesical4354614801311977109140190238289329351399448471
chemothe‑48456148013149107160248307339397450484
rapy850629801313282142189
and10636298013150107167
hyperthermia12546298013159105166220251288346399430520542590
in1869629801312280
the1973629801313391144
management21416298013190139197246305358447500558590
of2754629801315987
non‑muscle‑invasive28656298013159117176209300357396445467520554578635682732772793843894
bladder3783629801316184132192251304336
cancer:4142629801314999157206256288308
a44736298013150
systematic4547629801314190131165216305354386408457
review.5028629801313283132155207286301
Eur8506448013151107138
Urol.10126448013169100156179198
2011;12346448013153105153193204
60:14626448013154108126
81–93.16126448013154102151204253271
16.8506596013356107130
Halachmi10006596013372125150203251312402428
S,1448659601335477
Moskovitz15456596013389150192243302353379415464
B,2029659601336083
Maffezzini21326596013389142173205260307357382443468
M,26206596013389113
et2753659601335592
al.2866659601335378100
Intravesical2991659801312178110142192239291331353401451473
mitomycin34856598013190112145201291337385407464
C39706598013163
combined40546598013150105195255277335388448
with45236598013180102136194
hyperthermia47386598013159105166220252289347400431521543591
for850674801312986118
patients9926748013161111143165218275307349
with13656748013179102135193
T1G315826748013152102164216
transitional1822674801313466116174213235268290348406455477
cell23236748013149100123144
carcinoma2492674801314998130176198256314404452
of2968674801315987
the3080674801313492145
bladder.3249674801316084132192251304335349
Urol3623674801316899156179
Oncol.38266748013174133181237260279
2011;41296748013153105153193204
29(3):43576748013154105134184209226
259–264.46076748013154106155212260310366384
17.8506896013356104115
Sousa9886896013359120180223276
A,1292689601336792
Piñeiro1412689601335983143198223259318
I,1754689601333153
Rodríguez18366896013359119181217242303363418465
S,2324689601335982
et2429689601336096
al.2548689601335883106
Recirculant26786898013160114163185216263320342391449480
Hyperthermic31876898013170118179233264301359412444533555604
IntraVEsical3815689801312885117149199251302344365413463485
Chemotherapy43296898013163121174263321353411465496546605653
(HIVEC)50066898013134101124179231293323
in850704801312381
intermediate‑high‑risk955704801312380112163194284337398420468500551586645667726783817850872911956
non‑muscle‑invasive19357048013159118176209300357396445467520555578635683732772794843895
bladder2854704801316083132192251304335
cancer.3213704801314999157206256288302
Int3539704801312381113
J36767048013138
Hyperthermia.37387048013169117178232263300359412443533555603622
2016;43847048013154105153200217
32(4):46257048013154103128178203219
374–380.48697048013153101147204252304358376